## BARRETT'S ESOPHAGUS AND ESOPHAGEAL CANCER THE STATISTICS


Esophageal cancer typically affects people aged between 60 and 80 years. Together with gastric cancer, esophageal neoplasia accounts in Europe for around 6% of all cancers in men and 3% of all cancers in women.<sup>1</sup>




85% of Barrett's esophagus cases in Europe are undiagnosed.<sup>3,4</sup>



**Esophageal cancer** has the highest incidence in the UK, Netherlands and Ireland. Increase in population mortality for esophageal cancer is predicted to increase over the next 10 years.<sup>1</sup>



3% of all cancers in women.<sup>1</sup>



6% of all cancers in men.<sup>1</sup>



**GERD** and **Barrett's Esophagus** are risk
factors for Esophageal
Adenocarcinoma.<sup>2</sup>

Dysplastic Barrett's esophagus is associated with an increased risk of developing Esophageal Adenocarcinoma.<sup>3,4</sup>

11%

5-year survival rate of esophageal adenocarcinoma.<sup>5,6</sup> **6**×

Increase in the absolute incidence of esophageal adenocarcinoma (1973-2001).7



GREATER \$1B

Annual burden of illness in Europe.\*

- 1. Farthing, M., Roberts, S.E., Samuel, D.G., Williams, J.G., Thorne, K., Morrison-Rees, S., John, A. and Akbari, A. (2014) 'Survey of digestive health across Europe: Final report. Part 1: The burden of
- gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe', United European Gastroenterology Journal, 2(6), pp. 539–543. doi: 10.1177/2050640614554154
  2. Spechler et al., Barrett's Esophagus, New England Journal of Medicine 2014, 371:836-45.
- 3. Shaheen NJ, Sharma P, et al. Radiofrequency Ablation in Barrett's Esophagus with Dysplasia. New England Journal of Medicine. 2009 May;360(22):2277-2288.
- $4. \quad Bray F, et al. \ Estimates of global cancer prevalence for 27 sites in the adult population in 2008. \\ Int J Cancer. 2013 \ Mar 1;132(5):1133-45. \\ doi: 10.1002/ijc.27711. \\ Epub 2012 \ Jul 26. \\ Doi: 10.1002/ijc.27711. \\ Epub 2012 \ Jul 26. \\ Doi: 10.1002/ijc.27711. \\ Epub 2012 \ Jul 26. \\ Doi: 10.1002/ijc.27711. \\ Epub 2012 \ Jul 26. \\ Doi: 10.1002/ijc.27711. \\ Epub 2012 \ Jul 26. \\ Doi: 10.1002/ijc.27711. \\ Epub 2012 \ Jul 26. \\ Epub 2012 \ Jul 26.$
- 5. Sant M, et al. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. 2009 Apr;45(6):931-91. doi: 10.1016/j.ejca.2008.11.018. Epub 2009 Jan 24. 6. Ferlay J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013 Apr;49(6):1374-403. doi: 10.1016/j.ejca.2012.12.027.
- 7. Pohl H, Welch G, et al. The role of over diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142-6.

\*Internally derived estimate based on indirect costs in lost productivity in France (€555 million) from oesophageal cancer.



